- Home
- GPC vs GMAB Comparison
GPC vs GMAB Comparison
Compare GPC & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPC
- GMAB
- Stock Information
- Founded
- GPC 1928
- GMAB 1999
- Country
- GPC United States
- GMAB Denmark
- Employees
- GPC N/A
- GMAB N/A
- Industry
- GPC Automotive Aftermarket
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- GPC Consumer Discretionary
- GMAB Health Care
- Exchange
- GPC Nasdaq
- GMAB Nasdaq
- Market Cap
- GPC 18.6B
- GMAB 17.4B
- IPO Year
- GPC N/A
- GMAB N/A
- Fundamental
- Price
- GPC $126.83
- GMAB $30.86
- Analyst Decision
- GPC Buy
- GMAB Strong Buy
- Analyst Count
- GPC 6
- GMAB 6
- Target Price
- GPC $148.00
- GMAB $40.40
- AVG Volume (30 Days)
- GPC 1.1M
- GMAB 1.9M
- Earning Date
- GPC 10-21-2025
- GMAB 11-06-2025
- Dividend Yield
- GPC 3.26%
- GMAB N/A
- EPS Growth
- GPC N/A
- GMAB 132.41
- EPS
- GPC 5.81
- GMAB 25.10
- Revenue
- GPC $24,060,899,000.00
- GMAB $3,845,670,022.00
- Revenue This Year
- GPC $4.64
- GMAB $24.92
- Revenue Next Year
- GPC $3.67
- GMAB $15.97
- P/E Ratio
- GPC $21.78
- GMAB $1.23
- Revenue Growth
- GPC 3.26
- GMAB 29.57
- 52 Week Low
- GPC $104.01
- GMAB $17.24
- 52 Week High
- GPC $143.48
- GMAB $33.65
- Technical
- Relative Strength Index (RSI)
- GPC 45.31
- GMAB 58.52
- Support Level
- GPC $124.32
- GMAB $29.98
- Resistance Level
- GPC $130.21
- GMAB $30.82
- Average True Range (ATR)
- GPC 2.41
- GMAB 0.70
- MACD
- GPC 0.43
- GMAB 0.11
- Stochastic Oscillator
- GPC 55.98
- GMAB 82.06
About GPC Genuine Parts Company
Genuine Parts sells aftermarket automotive parts (60% of sales) and industrial products (40% of sales) in the United States and internationally. The automotive segment primarily acts as a distributor to its network of 9,800 global retail locations, of which about two-thirds are independently owned and operated. We estimate Genuine serves around 6,000 retail locations in the US operating under the Napa Auto Parts brand, with about 80% of end-market sales derived from professional customers. Its industrial segment, primarily operating under the Motion name in the United States, is a leading distributor of bearings, power transmission, and other industrial products to more than 200,000 maintenance, repair, and original equipment manufacturer customers.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.